DISTURBED ADIPONECTIN SECRETION IN PATIENTS WITH ASSOCIATED CHOLELITHIASIS AND TYPE 2 DIABETES MELLITUS

Cover Page

Cite item

Full Text

Abstract

Aim. To study adiponectin secretion and its disturbance in patients suffering from cholelithiasis (C) associated with type 2 diabetes mellitus (DM2). Materials and methods. Adiponectin secretion was studied in 22 patients with cholelithiasis associated with DM2, arterial hypertension (AH), nonalcoholic hepatic fatty disease (NAHFD), obesity (group 1) and in 10 women with polymorbid pathology, but without cholelithiasis (group 2). Results. Blood adiponectin level in patients of group 2 decreased as compared with its level in the group of young healthy women, respectively 14,26 ± 1,01 mkg/ml and 17,9 ± 1,15 mkg/ml ( p < 0,05). Blood adiponectin level in patients of group 1 was higher versus patients of group 2 and was equal to 15,79 ± 1,75 mkg.ml. Conclusions. Patients suffering from DM2 associated with obesity, AH, dislipidemia and, NAHFD had decreased adiponectin secretion. When cholelithiasis is associated with polymorbid pathology, a higher level of blood adiponectin is observed, despite lipid metabolism disorders and atherogenesis. So, delay of adiponectin secretion, caused by cholestasis in such patients, can’t be excluded.

About the authors

Ya A Kamenskikh

Пермский государственный медицинский университет имени академика Е.А. Вагнера

Email: kyara1@list.ru
аспирант кафедры эндокринологии и клинической фармакологии

References

  1. Беляева О.Д., Важенова Е.А., Березина А.В., Большакова О.О., Чубенко Е.А., Гаранина А.Е., Вадмаева М.И., Тимошин В.Б., Ларионова В.И., Баранова Е.И. Уровень адипонектина у пациентов с абдоминальным ожирением - носителей различных генотипов гена адипонектина. Вестник СПбГУ 2009; 11 (4): 36-48.
  2. Ивашкин В.Т., Маевская М.В., Павлов Ч.С., Тихонов И.Н., Широкова Е.Н., Буеверов А.О., Драпкина О.М., Шульпекова Ю.О., Цуканов В.В., Маммаев С.Н., Маев И.В., Пальгова Л.К. Клинические рекомендации по диагностике и лечению неалкогольной жировой болезни печени Российского общества по изучению печени и Российской гастроэнтерологической ассоциации. Гепатология 2016; 2: 24-42.
  3. Парфенова Н.С., Танянский Д.А. Адипонектин: благоприятное воздействие на метаболические и сердечно-сосудистые нарушения. Артериальная гипертензия 2013; 19 (1): 84-94.
  4. Савельева С.А., Крячкова A.A., Курумова К.О, Шамхалова М.Ш., Кутырина И.М., Шестакова М.В. Ожирение - фактор риска поражения почек у больных сахарным диабетом 2-го типа. Сахарный диабет 2010; 2: 45-50.
  5. Танянский Д.А., Фирова Э.М., Шатилина Л.В., Денисенко А.Д. Роль адипокинов и неэстерифицированных жирных кислот в развитии инсулинорезистентности. Проблемы эндокринологии 2009; 55 (3): 13-17.
  6. Al-Hamodi Z., Al-Habori M., Al-Meeri A., Saif-Ali R. Assosiation of adipokines , leptin/adiponectin ratio and C-reactive protein with obesity and tipe 2 diabetes mellitus. Diabetol Metab Syndr 2014; 6 (1): 99.
  7. Cantley J. The control of insulin secretion by adipokines: current evidence for adipocyte-beta cell endocrine signalling in metabolic homeostasis. Mamm Genome 2014; 25 (9-10): 442-454.
  8. Hwang J.Y., Park J.E., Choi Y.J., Huh K.B., Chang N., Kim W.Y. Carbohydrate intake interacts with SNP276G>T polymorphism in the adiponectin gene to affect fasting blood glucose, HbA1C, and HDL cholesterol in Korean patients with type 2 diabetes. J Am Coll Nutr 2013; 32 (3): 143-150.
  9. Kamari Y., Grossman E., Oron-Herman M., Peleg E., Shabtay Z., Shamiss A., Sharabi Y. Metabolic stress with a high carbohydrate diet increases adiponectin levels. Horm Metab Res 2007; 39 (5): 384-388.
  10. Kovacova Z., Tencerova M., Roussel B., Wedellova Z., Rossmeislova L., Langin D., Polak J., Stich V. The impact of obesity on secretion of adiponectin multimeric isoforms differs in visceral and subcutaneous adipose tissue. Int J Obes (Lond) 2012; 36 (10): 1360-1365.
  11. Ma H., Cui F., Dong J.J., You G.P., Yang X.J., Lu H.D., Huang Y.L. Therapeutic effects of globular adiponectin in diabetic rats with nonalcoholic fatty liver disease. World J Gastroenterol 2014; 20 (40): 14950-14957.
  12. Mallamaci F., Zoccali C., Cuzzola F., Tripepi G., Cutrupi S., Parlongo S., Tanaka S., Ouchi N., Kihara S., Funahashi T., Matsuzawa Y. Adiponectin in essential hypertension. J Nephrol 2002; 15 (5): 507-511.
  13. Ogiyama H., Kamada Y., Kiso S., Araki H., Yamada T., Nishihara T., Watabe K., Tochino Y., Kihara S., Funahashi T., Kanno K., Shimomura I., Tsutsui S., Tazuma S., Hayashi N. Lack of adiponectin promotes formation of cholesterol gallstones in mice. Biochem Biophys Res Commun 2010; 399 (3): 352-358.
  14. Tacke F., Wüstefeld T., Horn R., Luedde T., Srinivas Rao A., Manns MP., Trautwein C., Brabant G. High adiponectin in chronic liver disease and cholestasis suggests biliary route of adiponectin excretion in vivo. J Hepatol 2005; 42 (5): 666-673.
  15. Wang S.N., Yeh Y.T., Yu M.L., Dai C.Y., Chi W.C., Chung W.L., Lee K.T. Hyperleptinaemia and hypoadiponectinaemia are associated with gallstone disease. Eur J Clin Invest 2006; 36 (3): 176-180.

Copyright (c) 2016 Kamenskikh Y.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies